Several agents that individually target the EGFR or VEGFR pathways have been approved for the treatment of cancer, particularly non-small cell lung cancer (NSCLC); however, long-term efficacy of these agents as monotherapies is limited and resistance often occurs (Tabernero, 2007; Domvri et al, 2013). This evidence concerns the gene KDR and non-small cell lung carcinoma.